10-Year Growth of 870x! What's the Gap Between China's Innovative Drug Market and the US?

Yaozhi Data shows that from 2016 to 2025, the domestic innovative drug market size skyrocketed from less than 100 million yuan to nearly 50 billion yuan, a growth of over 8,700 times in ten years, demonstrating remarkable explosive growth.

However, when we look at the global landscape of innovative drugs, the United States accounts for over 50% of the global market share and is the absolute leader in innovative drugs worldwide. With a strong R&D foundation and an efficient approval system, the U.S. remains the global hub for innovative pharmaceuticals.

In the current wave of global pharmaceutical innovation, how is China’s innovative drug market catching up amid rapid growth? How is the gap with the U.S. evolving?

Note: The “China innovative drug market size” in this article refers to the sales share of Class 1 innovative drugs approved based on the 2016 chemical drug and 2020 traditional Chinese medicine and biologics new registration classifications.

01

Domestic Innovative Drug Market Continues to Expand

According to Yaozhi Data—the latest data from the full-endpoint drug sales analysis system—the domestic innovative drug market has achieved impressive growth from 2016 to 2025.

• From 2016 to 2025, sales of innovative drugs in China’s three major terminals (hospitals, retail, e-commerce) (Note: based on the sales share of Class 1 innovative drugs approved under the 2016 chemical drug and 2020 traditional Chinese medicine and biologics new registration classifications)

• Image source: Yaozhi Data—Full-Endpoint Drug Sales Analysis System

• Note: The sales data cutoff dates are: hospital end Q3 2025, retail end Q4 2025, e-commerce end Q4 2025.

From the data, it is clear that between 2016 and 2018, the total market size was relatively small, with combined sales not reaching 300 million yuan, mainly driven by a few star products, without forming a significant industry cluster.

The period from 2019 to 2020 marked the first explosive turning point. In 2019, the domestic innovative drug sales surged to 1.224 billion yuan, a significant jump from 161 million yuan in 2018; in 2020, sales doubled again to 3.149 billion yuan.

From 2021 to 2025, the domestic innovative drug market experienced rapid growth, with the market size expanding exponentially. Sales reached 8.866 billion yuan in 2021, surpassed 17 billion yuan in 2022, and by 2025, it is approaching 50 billion yuan (Note: 2025 data does not include hospital Q4 sales).

From 0.56 billion yuan in 2016 to 48.975 billion yuan in 2025, the market has grown over 870 times in ten years, directly reflecting the astonishing growth rate of China’s innovative drug industry.

In terms of sales terminal distribution, hospitals have always been the main battlefield for domestic innovative drugs, with sales rising from 47 million yuan in 2016 to 31.7 billion yuan in 2025, accounting for 65%, maintaining an absolute dominant position.

Meanwhile, retail and e-commerce channels have steadily risen, promoting diversified access to innovative drugs. From 2016 to 2019, the share of innovative drug sales in retail terminals increased from 14.8% to 46.8%; by 2025, it accounts for 32.8%, becoming the most important market supplement outside hospitals. Since 2019, e-commerce terminals have experienced explosive growth, with sales reaching 1.21 billion yuan in 2025, a several-thousand-fold increase from 22 million yuan in 2019, becoming a new growth driver in the industry.

Behind the rapid growth of China’s innovative drug market are policy support, market demand, technological advances, and other factors forming a synergistic development.

In 2015, the State Council’s drug review reform policies were implemented, officially signaling the push for “improving review and approval quality and encouraging innovative drugs.” Subsequently, a series of supporting policies such as priority review, breakthrough therapy designation, and conditional approval were introduced, significantly shortening the R&D and commercialization cycle of new drugs.

By 2025, the National Medical Products Administration (NMPA) approved 76 innovative drugs for market launch, covering diverse categories such as antibody drugs, recombinant proteins, and cell and gene therapies. Not only did the number reach a historic high, but there is also an accelerating trend of cutting-edge therapies from around the world being rapidly introduced into China, greatly enriching clinical options for domestic patients.

On the payment side, the National Healthcare Security Administration (NHSA) has established a “fast track” for innovative drugs into the medical insurance catalog through annual regular adjustments. Since 2018, over 140 innovative drugs have been included in the national drug list. For example, in the first half of 2025, 43 new drugs approved for insurance inclusion, with 30 successfully negotiated into the catalog, achieving a coverage rate of 70%.

As of May 2025, the medical insurance fund has paid a total of 410 billion yuan for negotiated drugs during the agreement period, driving sales of related drugs to over 600 billion yuan. Strong insurance payment support not only ensures patient access but also fuels continuous R&D investment by innovative drug companies.

Meanwhile, multinational pharmaceutical companies are deepening their strategic presence in China, leveraging favorable policies from the drug review reform to integrate China into the global R&D system, and quickly bringing high-quality innovative drugs to the Chinese market.

Major approvals include Takeda’s trastuzumab deruxtecan, AstraZeneca’s capecitabine, and others, reshaping treatment paradigms for breast cancer and solid tumors; Sanofi’s calasizumab, Novartis’ asciminib, and other globally first-in-class drugs have entered China, filling gaps in rare diseases and hematologic tumors; multiple long-acting GLP-1 receptor agonists, bispecific antibodies, and CAR-T cell therapies have been rapidly introduced, allowing domestic patients to access top-tier global therapies simultaneously. The dense arrival of imported innovative drugs will further drive the expansion and upgrading of the domestic innovative drug market.

02

Multi-Dimensional Comparison of China and U.S. Innovative Drug Markets

According to Evaluate Pharma, the global prescription drug market was valued at $1.1 trillion in 2024, with projections to exceed $1.7 trillion by 2030, with innovative drugs becoming the core growth driver.

Image source: Evaluate Pharma

From the global innovation landscape, the U.S. remains the dominant force. According to the 2023 annual report of BaiCheng Pharma, the U.S. innovative drug market was valued at $474.5 billion in 2022, with a compound annual growth rate (CAGR) of 5.7% from 2018 to 2022; Frost & Sullivan forecasts that by 2030, the U.S. market will reach $684.4 billion.

Research reports from Dongwu Securities indicate that, thanks to mature payment ecosystems and pricing systems, the U.S. has long maintained the largest global innovative drug market, with U.S. sales accounting for over 50% of the global total. In comparison, China’s current innovative drug sales account for about 3% of the global market, but the growth potential remains substantial.

In terms of R&D pipelines, the U.S. boasts the world’s largest pipeline of innovative drugs, leading in the total number of candidates, breadth of indications, and number of first-in-class drugs. Over the past decade, China’s pipeline expansion has been leading globally, with the number of candidates growing at a double-digit rate since 2010. From 2016 to 2024, the number of ongoing drugs in China increased from over 1,000 to 6,000+, while the U.S. grew from nearly 8,000 to 11,200+. By the end of 2024, China’s active innovative drug count topped the global list.

Regarding approval efficiency, the U.S. FDA has a mature NDA/BLA approval system, with mechanisms like accelerated review and breakthrough therapy designation allowing nearly half of new drugs to be approved within 300 days, making approval efficiency and predictability globally leading. China, after reforming its drug review system, introduced priority review and conditional approval, significantly shortening the time to market for first-in-class drugs. Some products, such as PD-1/VEGF bispecifics and EGFR ADCs, have achieved global simultaneous approval. From 2018 to 2024, the number of Class 1 innovative drugs approved in China has steadily increased, reaching 48 in 2024, close to the 50 NME approvals in the U.S.

China’s large population base, aging demographics, and proactive government policies promoting innovation are driving the development of its innovative drug market. Additionally, dynamic adjustments in medical insurance, increased R&D spending, and other factors further support growth. According to BaiCheng Pharma’s 2023 annual report, China’s innovative drug market reached 958.9 billion yuan in 2022, with a CAGR of 3.0% from 2018 to 2022, and is projected to grow to 1.9725 trillion yuan by 2030.

Based on BaiCheng Pharma’s data, rough estimates suggest that in 2022, the U.S. innovative drug market was about 3.5 times larger than China’s. By 2030, the gap is expected to narrow, with the U.S. market approximately 2.4 times the size of China’s (assuming an exchange rate of 1 USD = 7 RMB).

Overall, the U.S. still holds clear advantages in core innovation capabilities, basic research depth, number of globally first-in-class drugs, and capital support.

Meanwhile, China’s aging population, rising prevalence of chronic diseases such as tumors, autoimmune diseases, and metabolic disorders, and the persistent demand for high-efficacy, high-safety innovative drugs will further drive rapid expansion of the domestic market.

03

Insights Behind Competitive Differentiation

The internationalization of innovative drugs is fundamentally a breakthrough in value realization. Comparing two benchmark drugs from China and the U.S. clearly illustrates successful differentiation strategies.

BeiGene’s Zepzelca (Zebutinib) is a flagship example of China’s innovative drug globalization. According to BeiGene’s 2025 performance report, Zepzelca’s global sales reached $3.9 billion (about 280.67 billion RMB) in that year, up 49% year-over-year, making it the first domestically developed innovative drug to enter the global “$1 billion club,” with notable sales differences between China and the U.S.

In the U.S., Zepzelca’s 2025 sales were $2.8 billion (about 202.06 billion RMB), up 45%, accounting for 71.8% of global sales. The U.S. remains BeiGene’s largest commercial market. Its success hinges on a differentiated global strategy: in the U.S., it demonstrated superior efficacy through head-to-head clinical trials, obtained FDA breakthrough therapy designation, and adopted high pricing strategies to capture market share. Additionally, its approved indications cover multiple areas such as CLL/SLL, with broad market coverage. In 2025, it held a 33.8% share of the BTK inhibitor market in the U.S., surpassing Ibrutinib to become the leader.

In China, Zepzelca’s 2025 sales were $340 million (about 2.472 billion RMB), up 33.3% year-over-year, representing 8.7% of global sales. In China, it achieved rapid volume growth through insurance negotiations, benefiting more patients.

The core of Zepzelca’s success lies in its differentiated global deployment strategy, especially the dual registration pathways in China and the U.S., enabling synchronized commercialization. This approach leverages high pricing and growth in the U.S. while expanding volume in China, maximizing global sales.

Eli Lilly’s Taltz (ixekizumab) achieved over $3.65 billion in sales in 2025, securing its position as a “top-selling drug,” with the U.S. as its main growth engine. Approved in the U.S. in 2022, it entered China later. In terms of payment, U.S. commercial insurance covers indications such as psoriasis and psoriatic arthritis, and the high awareness and demand for obesity treatment in the U.S. have fueled explosive growth. In contrast, in China, only the psoriasis indication is covered by insurance, with the weight-loss market still in development, reflecting differences in payment capacity and market maturity between the two countries.

These comparisons and benchmark cases offer valuable insights for domestic pharmaceutical companies’ innovation strategies.

By aligning with the disease spectrum characteristics of Chinese patients—focusing on high-incidence diseases like liver and gastric cancers, which are less common in the West—companies can turn local clinical needs into global competitive advantages and improve drug clinical adaptability.

Learning from Zepzelca’s experience, companies should develop multi-center global clinical trials, simultaneously apply for approvals in China, the U.S., Europe, and Japan, and achieve synchronized approvals domestically and internationally. Through licensing-out and other strategies, they can build a global commercialization network, prioritize high-end markets in the U.S. and Europe, and enhance brand recognition worldwide.

In overseas markets like the U.S., efforts should focus on demonstrating clinical value to secure high pricing and pricing power. In China, active participation in insurance negotiations and leveraging emerging payment channels such as the “Commercial Health Insurance Innovative Drug List” can expand payment options for high-value drugs not yet covered by insurance.

04

Conclusion

Over the past decade, China’s innovative drug market has undergone a magnificent transformation, but compared to mature markets like the U.S. and EU, it still lags in core innovation and global commercialization capabilities.

Looking ahead, with continuous improvement of insurance and payment systems, a shift toward original innovation in R&D, and accelerated globalization, China’s innovative drug industry is poised for a new wave of explosive growth.